Shu‐Chuan Weng
Papers
1
Total Citations
16
H-Index
1
About
Dr. Shu‐Chuan Weng is a distinguished urologic surgeon and researcher whose work centers on advancing minimally invasive treatments for benign prostatic obstruction (BPO), particularly in aging males with large prostates. His major contributions lie in comparative effectiveness research, where he has systematically evaluated and refined surgical techniques such as endoscopic enucleation of the prostate (including ThuLEP and bipolar TUEP) against robotic-assisted simple prostatectomy. His landmark 2021 study, which has garnered 16 citations, provides critical clinical evidence guiding treatment selection for prostates larger than 80 cm³—a challenging patient population. By analyzing outcomes from 2014 to 2020, Dr. Weng has helped establish safety and efficacy benchmarks that directly inform urologic practice. His work is notable for its rigorous exclusion criteria and focus on real-world patient outcomes, excluding those with active malignancies or neurogenic bladder to ensure data purity. Through these contributions, Dr. Weng has become a key voice in the ongoing evolution of BPO surgery, helping to balance the benefits of endoscopic and robotic approaches for improved recovery and quality of life in older men.
Research Focus
Key Achievements
Top Papers
- 1